Naja Nyffenegger Selected Research

VIT-2763

1/2021	The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
12/2019	Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naja Nyffenegger Research Topics

Disease

3	Thalassemia 10/2023 - 12/2019
3	Anemia 10/2023 - 12/2019
3	Iron Overload 10/2023 - 12/2019
1	Hemolytic Anemia 01/2022
1	Sickle Cell Anemia (Hemoglobin S Disease) 01/2022
1	Hemolysis 01/2022
1	Inflammation (Inflammations) 01/2022
1	beta-Thalassemia (Cooley's Anemia) 12/2019

Drug/Important Bio-Agent (IBA)

4	metal transporting protein 1 (ferroportin)IBA 10/2023 - 12/2019
4	IronIBA 10/2023 - 12/2019
2	GlobinsIBA 01/2022 - 12/2019
2	VIT-2763IBA 01/2021 - 12/2019
1	Transferrin (beta 2 Transferrin)IBA 10/2023
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	Heme (Haem)IBA 01/2022
1	Sickle HemoglobinIBA 01/2022
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2022
1	Chelating AgentsIBA 01/2021
1	Deferasirox FDA Link 01/2021
1	HepcidinsIBA 12/2019
1	Hormones (Hormone)IBA 12/2019

Therapy/Procedure

1	Blood Transfusion (Blood Transfusions) 10/2023
1	Chelation Therapy (Therapy, Chelation) 01/2021